Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders purchased 32,455 put options on the company. This represents an increase of ...

Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Jones Financial Companies Lllp boosted its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.2% in the 4th quarter, ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.

High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...